Clearmind Medicine Completes Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Clearmind Medicine completes initiation of leading Israeli clinical site for Phase I/IIa trial of CMND-100 in Alcohol Use Disorder. The trial, already underway at prestigious US sites, assesses the safety, tolerability, and pharmacokinetic profile of CMND-100 and explores early efficacy signals in patients with AUD. CMND-100, Clearmind's lead compound, has shown promising results in reducing alcohol cravings in preclinical studies.

Title: Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Clearmind Medicine Inc. (Nasdaq: CMND) has successfully completed the site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial of CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milestone advances Clearmind’s mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually [1].

The Phase I/IIa trial, already underway at prestigious sites including Yale School of Medicine and Johns Hopkins University in the United States, is now expanded to include TASMC and Hadassah-University Medical Center in Israel. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing early efficacy signals in reducing alcohol cravings and consumption. The inclusion of TASMC as a clinical site, led by Prof. David Zeltser, Director of the Emergency Medicine Department at TASMC, strengthens Clearmind’s clinical network and accelerates patient enrollment in this groundbreaking trial [2].

CMND-100, Clearmind's lead compound, leverages the innovative molecule 5-methoxy-2-aminoindane (MEAI) to offer a potential breakthrough in AUD treatment. Preclinical studies have shown promising results in reducing alcohol cravings, positioning CMND-100 as a potentially novel therapeutic in a market with significant demand. The company emphasizes its non-hallucinogenic properties, differentiating it from classic psychedelics while still leveraging novel CNS pathways [1].

The clinical significance of CMND-100 is substantial, given the global impact of AUD and the lack of effective pharmacotherapies available. Adding TASMC expands patient recruitment capacity, potentially accelerating study completion and advancing the program toward pivotal trials if early results prove promising. Clearmind Medicine is committed to addressing this critical unmet need and transforming treatment for AUD [2].

References
[1] https://www.stocktitan.net/news/CMND/clearmind-medicine-completes-initiation-of-leading-israeli-clinical-dsi0xn6ry9b6.html
[2] https://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Completes+Initiation+of+Leading+Israeli+Clinical+Site+for+Phase+IIIa+Trial+of+CMND-100+in+Alcohol+Use+Disorder/25084895.html